These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 36991534)

  • 1. Structure-based engineering of a novel CD3ε-targeting antibody for reduced polyreactivity.
    Liu CY; Ahonen CL; Brown ME; Zhou L; Welin M; Krauland EM; Pejchal R; Widboom PF; Battles MB
    MAbs; 2023; 15(1):2189974. PubMed ID: 36991534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors.
    Root AR; Guntas G; Katragadda M; Apgar JR; Narula J; Chang CS; Hanscom S; McKenna M; Wade J; Meade C; Ma W; Guo Y; Liu Y; Duan W; Hendershot C; King AC; Zhang Y; Sousa E; Tam A; Benard S; Yang H; Kelleher K; Jin F; Piche-Nicholas N; Keating SE; Narciandi F; Lawrence-Henderson R; Arai M; Stochaj WR; Svenson K; Mosyak L; Lam K; Francis C; Marquette K; Wroblewska L; Zhu HL; Sheehan AD; LaVallie ER; D'Antona AM; Betts A; King L; Rosfjord E; Cunningham O; Lin L; Sapra P; Tchistiakova L; Mathur D; Bloom L
    MAbs; 2021; 13(1):1850395. PubMed ID: 33459147
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single cell-produced and in vitro-assembled anti-FcRH5/CD3 T-cell dependent bispecific antibodies have similar in vitro and in vivo properties.
    Ovacik AM; Li J; Lemper M; Danilenko D; Stagg N; Mathieu M; Ellerman D; Gupta V; Kalia N; Nguy T; Plaks V; David Johnson C; Wang W; Brumm J; Fine B; Junttila T; Lin K; Carter PJ; Prabhu S; Spiess C; Kamath AV
    MAbs; 2019; 11(2):422-433. PubMed ID: 30550367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies.
    Skokos D; Waite JC; Haber L; Crawford A; Hermann A; Ullman E; Slim R; Godin S; Ajithdoss D; Ye X; Wang B; Wu Q; Ramos I; Pawashe A; Canova L; Vazzana K; Ram P; Herlihy E; Ahmed H; Oswald E; Golubov J; Poon P; Havel L; Chiu D; Lazo M; Provoncha K; Yu K; Kim J; Warsaw JJ; Stokes Oristian N; Siao CJ; Dudgeon D; Huang T; Potocky T; Martin J; MacDonald D; Oyejide A; Rafique A; Poueymirou W; Kirshner JR; Smith E; Olson W; Lin J; Thurston G; Sleeman MA; Murphy AJ; Yancopoulos GD
    Sci Transl Med; 2020 Jan; 12(525):. PubMed ID: 31915305
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms of CD3epsilon in cynomolgus and rhesus monkeys and their relevance to anti-CD3 antibodies and immunotoxins.
    Liu YY; Wang Z; Thomas J; Goodwin KJ; Stavrou S; Neville DM
    Immunol Cell Biol; 2007 Jul; 85(5):357-62. PubMed ID: 17325695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative Target Affinities of T-Cell-Dependent Bispecific Antibodies Determine Biodistribution in a Solid Tumor Mouse Model.
    Mandikian D; Takahashi N; Lo AA; Li J; Eastham-Anderson J; Slaga D; Ho J; Hristopoulos M; Clark R; Totpal K; Lin K; Joseph SB; Dennis MS; Prabhu S; Junttila TT; Boswell CA
    Mol Cancer Ther; 2018 Apr; 17(4):776-785. PubMed ID: 29339550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release.
    Zuch de Zafra CL; Fajardo F; Zhong W; Bernett MJ; Muchhal US; Moore GL; Stevens J; Case R; Pearson JT; Liu S; McElroy PL; Canon J; Desjarlais JR; Coxon A; Balazs M; Nolan-Stevaux O
    Clin Cancer Res; 2019 Jul; 25(13):3921-3933. PubMed ID: 30918018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody.
    Staflin K; Zuch de Zafra CL; Schutt LK; Clark V; Zhong F; Hristopoulos M; Clark R; Li J; Mathieu M; Chen X; Johnston J; Low J; Ybarra R; Slaga D; Yang J; Ovacik M; Dybdal NO; Totpal K; Junttila MR; Ellerman D; Lee G; Dennis MS; Prell R; Junttila TT
    JCI Insight; 2020 Apr; 5(7):. PubMed ID: 32271166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction of a novel TROP2/CD3 bispecific antibody with potent antitumor activity and reduced induction of Th1 cytokines.
    Wang D; Zhang L; Wang B; Zhao L; Deng L; Xu W; Huang H
    Protein Expr Purif; 2023 May; 205():106242. PubMed ID: 36746324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of an amino acid responsible for the CD3 polymorphism in cynomolgus monkeys (Macaca fascicularis).
    Uda A; Tanabayashi K; Mukai R; Terao K; Yamada A
    J Med Primatol; 2003 Apr; 32(2):105-10. PubMed ID: 12823633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia.
    Friedrich M; Henn A; Raum T; Bajtus M; Matthes K; Hendrich L; Wahl J; Hoffmann P; Kischel R; Kvesic M; Slootstra JW; Baeuerle PA; Kufer P; Rattel B
    Mol Cancer Ther; 2014 Jun; 13(6):1549-57. PubMed ID: 24674885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An anti-CD3/anti-CLL-1 bispecific antibody for the treatment of acute myeloid leukemia.
    Leong SR; Sukumaran S; Hristopoulos M; Totpal K; Stainton S; Lu E; Wong A; Tam L; Newman R; Vuillemenot BR; Ellerman D; Gu C; Mathieu M; Dennis MS; Nguyen A; Zheng B; Zhang C; Lee G; Chu YW; Prell RA; Lin K; Laing ST; Polson AG
    Blood; 2017 Feb; 129(5):609-618. PubMed ID: 27908880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class.
    Brischwein K; Parr L; Pflanz S; Volkland J; Lumsden J; Klinger M; Locher M; Hammond SA; Kiener P; Kufer P; Schlereth B; Baeuerle PA
    J Immunother; 2007; 30(8):798-807. PubMed ID: 18049331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats.
    Moore GL; Bernett MJ; Rashid R; Pong EW; Nguyen DT; Jacinto J; Eivazi A; Nisthal A; Diaz JE; Chu SY; Muchhal US; Desjarlais JR
    Methods; 2019 Feb; 154():38-50. PubMed ID: 30366098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD3 polymorphism in cynomolgus monkeys (Macaca fascicularis).
    Uda A; Tanabayashi K; Mukai R; Yachi M; Nam KH; Yamada A
    J Med Primatol; 2001 Jun; 30(3):141-7. PubMed ID: 11515669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing.
    Engelberts PJ; Hiemstra IH; de Jong B; Schuurhuis DH; Meesters J; Beltran Hernandez I; Oostindie SC; Neijssen J; van den Brink EN; Horbach GJ; Verploegen S; Labrijn AF; Salcedo T; Schuurman J; Parren PWHI; Breij ECW
    EBioMedicine; 2020 Feb; 52():102625. PubMed ID: 31981978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering a bispecific antibody with a common light chain: Identification and optimization of an anti-CD3 epsilon and anti-GPC3 bispecific antibody, ERY974.
    Shiraiwa H; Narita A; Kamata-Sakurai M; Ishiguro T; Sano Y; Hironiwa N; Tsushima T; Segawa H; Tsunenari T; Ikeda Y; Kayukawa Y; Noguchi M; Wakabayashi T; Sakamoto A; Konishi H; Kuramochi T; Endo M; Hattori K; Nezu J; Igawa T
    Methods; 2019 Feb; 154():10-20. PubMed ID: 30326272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies.
    Sun LL; Ellerman D; Mathieu M; Hristopoulos M; Chen X; Li Y; Yan X; Clark R; Reyes A; Stefanich E; Mai E; Young J; Johnson C; Huseni M; Wang X; Chen Y; Wang P; Wang H; Dybdal N; Chu YW; Chiorazzi N; Scheer JM; Junttila T; Totpal K; Dennis MS; Ebens AJ
    Sci Transl Med; 2015 May; 7(287):287ra70. PubMed ID: 25972002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate.
    Waaijer SJ; Giesen D; Ishiguro T; Sano Y; Sugaya N; Schröder CP; de Vries EG; Lub-de Hooge MN
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A humanized, bispecific immunoadhesin-antibody that retargets CD3+ effectors to kill HIV-1-infected cells.
    Chamow SM; Zhang D; Tan XY; Mhatre SM; Marsters SA; Peers DH; Byrn RA; Ashkenazi A; Junghans RP
    J Hematother; 1995 Oct; 4(5):439-46. PubMed ID: 8581382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.